Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
Thromboembolism
Primary: Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 — 85.2001; 42.6837; 73.7641; 12.1027 microgram per liter (mcg/L)
Phase 2 N=483 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Migraine
Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -2.28; -2.18; -2.39; -3.40 migraine days / month — p=0.021
Phase 2 N=158 A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response up to 24 Weeks — 18.1; 17.7; 17.0; 15.0 percentage of participants — p=0.059
Phase 2 N=27 Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9 — -2.604; -3.797; -4.484 μM — p=<0.0001
Phase 2 N=24 TPI 287 in Breast Cancer Metastatic to the Brain
Breast Cancer
Primary: Overall Response Rate (ORR) — 21 Participants
Phase 2 N=45 Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple…
Phase 2 N=45 Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Aplastic Anemia · Leukemia · Myelodysplastic Syndrome
Primary: Successful Neutrophil Engraftment — 44; 1 Participants
Phase 2 N=31 Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus
Asthma
Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59
Phase 2 N=14 Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine
Homocystinuria
Primary: Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine…
Phase 2 N=70 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Tumor · Breast Cancer
Primary: Objective Response Rate (ORR) — 28.6; 35 percentage of subjects
Phase 2 N=70 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 90.9; 90.0; 44.4 percentage of participants
Phase 2 N=55 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants
Phase 2 N=13 A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
Advanced Metastatic (Stage IV) Colorectal Cancer
Primary: Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia) — 14; 11; 6…
Phase 2 N=50 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
Tinea Pedis
Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants